Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 16, Number 2—February 2010

Letter

Detection of Pandemic (H1N1) 2009 Virus in Patients Treated with Oseltamivir

Suggested citation for this article

To the Editor: In April 2009, an influenza outbreak caused by a novel strain of influenza virus A (H1N1) was identified in Mexico. The rapid spread of this new virus among humans led the World Health Organization to raise the phase of pandemic alert to 6. We report results from the 2 virology laboratories from university hospitals that were involved in the surveillance network of pandemic (H1N1) 2009 in Paris at the beginning of the outbreak in France.

Patients exhibiting influenza-like illness (i.e., fever, sore throat, cough, asthenia, headache, myalgia) and who recently had traveled to countries where the pandemic (H1N1) 2009 outbreak had started (i.e., Mexico, United States, Canada, Japan) were hospitalized. Symptoms began either the day before or the day of hospitalization. Nasal-swab specimens were collected at admission by using the Virocult system (ELITech; Salon-de-Provence, France), and treatment with oseltamivir was started (75 mg, 2×/day). Pandemic (H1N1) 2009 infection was diagnosed by using rapid test QuickVue Influenza A+B (Quidel, San Diego, CA, USA) and real-time reverse transcription–PCR (RT-PCR) assays from the French National Influenza Centers or the US Centers for Disease Control and Prevention (1). In the case of a positive result, influenza virus in nasal secretions from patients was monitored daily by RT-PCR until viral genomes became undetectable.

Figure

Thumbnail of Duration of pandemic (H1N1) 2009 excretion in nasal swabs from patients treated with oseltamivir. The number of days from start of oseltamivir treatment to achievement of negative results of reverse transcription–PCR (RT-PCR) is indicated for 16 patients. The 3 patients classified in the last group (>5 days) are 1 patient with a negative RT-PCR result on day 7 posttreatment and 2 patients who still had positive results on day 5 posttreatment but provided no additional sample for

Figure. Duration of pandemic (H1N1) 2009 excretion in nasal swabs from patients treated with oseltamivir. The number of days from start of oseltamivir treatment to achievement of negative results of reverse transcription–PCR...

From April 24 through June 7, 2009, nasal swab specimens from 234 persons (132 men; median age of all patients 33 years) were processed; pandemic (H1N1) 2009 infection was confirmed for 17 men and 15 women (median age 33 years) by RT-PCR. Results of the Quidel rapid tests were available for 27 specimens, with positive results for 9 (33% sensitivity). However, no positive result was observed with the Quidel rapid tests among the nasal-swab specimens with negative RT-PCR results (100% specificity). Influenza virus detection in nasal secretions was monitored for 16 patients who had laboratory-confirmed pandemic (H1N1) 2009 infection and were treated with oseltamivir. Viral detection by RT-PCR was absent 2 to >5 days after antiviral treatment began (Figure). Significant differences were not found in sex and age of the patients (data not shown).

These preliminary virologic data obtained during the first 6 weeks of pandemic (H1N1) 2009 in France confirm the poor sensitivity of the Quidel test toward this new virus, as recently reported (2). Further studies are needed to evaluate the performances of other rapid tests. Hayden et al. (3) demonstrated that treatment with oseltamivir significantly reduced duration of viral shedding among patients infected with seasonal influenza virus A (H1N1), in comparison with a placebo group: 1.5–2.5 days vs. 3.5–5.5 days (p = 0.003). In our study, surprisingly, PCR results for sequential nasal swab specimens from 16 patients infected by pandemic (H1N1) 2009 and treated with oseltamivir were negative within 3 days after therapy for only 9 (56%); indeed, for 3 (19%) patients, viral genome could be detected >5 days after antiviral treatment began. These data raise questions about potential virus transmission during antiviral treatment and the possible resistance of pandemic (H1N1) 2009 to oseltamivir. This latter point is now under study.

David BoutolleauComments to Author , Nadhira Houhou, Claire Deback, Henri Agut, and Françoise Brun-Vézinet
Author affiliations: Université Pierre et Marie Curie 6, Paris, France; (D. Boutolleau, C. Deback, H. Agut); Pitié-Salpêtrière University Hospitals, Paris (D. Boutolleau, C. Deback, H. Agut); Bichat-Claude Bernard University Hospital, Paris (N. Houhou, F. Brun-Vézinet)

Acknowledgment

We thank the members of diagnostic section of the Influenza Research Group of the Institute for Microbiology and Infectious Diseases for their constant support and assistance in these investigations. We also thank the physicians from the Infectious Disease departments of Pitié-Salpêtrière and Bichat-Claude Bernard University Hospitals, who were deeply involved in the management of patients infected by pandemic (H1N1) 2009.

References

  1. Collaborating WHO. Center for Influenza. CDC protocol of realtime RTPCR for influenza A (H1N1). 28 April 2009. Geneva: World Health Organization; 2009 [cited 2009 Jun 23]. http://www.who.int/csr/resources/publications/swineflu/realtimertpcr/en/index/html
  2. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;361:7289. DOIPubMed
  3. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:12406. DOIPubMed

Figure

Suggested citation for this article: Boutolleau D, Houhou N, Deback C, Agut H, Brun-Vézinet F. Detection of pandemic (H1N1) 2009 in patients treated with oseltamivir [letter]. Emerg Infect Dis [serial on the Internet]. 2010 Jan [date cited]. Available from http://wwwnc.cdc.gov/eid/article/16/2/09-1328.htm

DOI: 10.3201/eid1602.091328

Related Links

Top of Page

Table of Contents – Volume 16, Number 2—February 2010

Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

David Boutolleau, Virology Department, Pitié-Salpêtrière University Hospital, 83 blvd de l’Hôpital, F-75013 Paris, France





characters(s) remaining.

Comment submitted successfully, thank you for your feedback.

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO